Healthcare Technologies International (HTI) has announced that it recently transferred shares of its ownership in two of the largest Managed Equipment Services (MES) companies in the UK to Medipass Healthcare Ltd for an undisclosed sum.
HTI pioneered the first cancer specific Managed Equipment Service in the UK with partnerships at the Belfast Health & Social Care Trust and the Leeds Teaching Hospitals Trust.
The first ever MES of its kind in the UK, the Cancer Centre at Belfast City Hospital was opened in 2006 with design consultation and radiotherapy and diagnostic equipment being installed and managed by HTI under a 25 year concession.
Following on from the success of its Belfast project, HTI provided design and development consultation along with equipment management for the UK’s largest cancer centre, housed in the Bexley Wing at St James’s University Hospital, Leeds, under a 15 year Managed Equipment Services agreement.
Ron Gilden, CEO of HTI said:
As part of our long-term growth strategy we are pleased to work with Medipass Healthcare in new MES projects and have successfully negotiated with them for the transfer of our shares in HTI Ireland and HTI Leeds.
This allows HTI the maneuverability and financial strength to continue to meet the growing demand for NHS cooperative private patient units and satellite radiotherapy centres to be developed throughout the UK.
HTI was recently selected as the Preferred Bidder to develop the Satellite Radiotherapy Unit for Guy’s and St Thomas’s NHS Foundation Trust, London. HTI also continues to develop and operate private patient units such as its Nova Healthcare brand located within the Bexley Wing of the St. James’s Institute of Oncology.
This unit is provided through a strategic partnership with the Leeds Teaching Hospitals Trust and consists of the Leeds Gamma Knife Centre, treating both NHS and private patients with advanced stereotactic radiosurgery, and the Leeds Prostate Centre, offering advanced robotic surgery for private patients.
Mr Gilden added:
HTI will continue its strong commitment to the NHS with new projects in the UK. Our company will work diligently with our existing NHS partners as well as new ones to ensure that public patients benefit from increasing private patient revenues and access to specialised services that are currently not available within the NHS.
This means that in addition to the development of satellite units in partnership with NHS hospitals throughout the UK, we also plan to grow our private patient services and offer greater access to advanced cancer therapies such as proton treatment.
HTI is also currently developing a number of proton therapy centres throughout the EU.